ConductScience.org, home

Paper39726468

Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.

García-Méndez JO and 9 others. Cureus, 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients. Papers, record 39726468. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39726468

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Clinical Experience With Ivermectin and Nitazoxanide in the Management of COVID-19 Among Mexican Out- and Inpatients.
PubMed
Journal
Cureus
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2025-01-04
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1García-Méndez JOJorge O
2Fernández-Garza LELuis E
3Vallejo-Oviedo KKaren
4Gómez-Curiel DIDiana I
5Barrera-Barrera SASilvia A
6Ordaz-Cuellar RRosario
7Sosa-García JOJesús O
8García-Torrentera RARogelio A
9Cervera EEduardo
10Barrera-Saldaña HAHugo A

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References33

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136317748Clinical outcomes, virological efficacy and safety of nitazoxanide in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.Expert Rev Anti Infect Ther2022https://conductscience.org/library/papers/36317748PubMed
233065103Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study.Chest2021https://conductscience.org/library/papers/33065103PubMed
332020029Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Res2020https://conductscience.org/library/papers/32020029PubMed
432895293Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19.Open Heart2020https://conductscience.org/library/papers/32895293PubMed
532878619COVID-19 length of hospital stay: a systematic review and data synthesis.BMC Med2020https://conductscience.org/library/papers/32878619PubMed
635870876Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype.BMC Infect Dis2022https://conductscience.org/library/papers/35870876PubMed
734623777Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis.Infect Chemother2021https://conductscience.org/library/papers/34623777PubMed
832533071Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.J Antibiot (Tokyo)2020https://conductscience.org/library/papers/32533071PubMed
933723507Use of ivermectin in the treatment of Covid-19: A pilot trial.Toxicol Rep2021https://conductscience.org/library/papers/33723507PubMed
1034181716Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Clin Infect Dis2022https://conductscience.org/library/papers/34181716PubMed
1132584326CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF PATIENTS DIAGNOSED WITH COVID-19 IN A TERTIARY CARE CENTER IN MEXICO CITY: A PROSPECTIVE COHORT STUDY.Rev Invest Clin2020https://conductscience.org/library/papers/32584326PubMed
1235325252Correction to: Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis.QJM2022https://conductscience.org/library/papers/35325252PubMed
1333361100Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.Eur Respir J2021https://conductscience.org/library/papers/33361100PubMed
1432344460The potential for COVID-19 to contribute to compassion fatigue in critical care nurses.J Clin Nurs2020https://conductscience.org/library/papers/32344460PubMed
1515791519Nitazoxanide: a new thiazolide antiparasitic agent.Clin Infect Dis2005https://conductscience.org/library/papers/15791519PubMed
1636066651Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.Eur J Clin Pharmacol2022https://conductscience.org/library/papers/36066651PubMed
1733590901Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.J Med Virol2021https://conductscience.org/library/papers/33590901PubMed
1832725536A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19.Infect Dis Ther2020https://conductscience.org/library/papers/32725536PubMed
1934145166Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.Am J Ther2021https://conductscience.org/library/papers/34145166PubMed
2033067035Coagulation and anticoagulation in COVID-19.Blood Rev2021https://conductscience.org/library/papers/33067035PubMed

See all 33 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401NCBI Gene
FGB2244PubTator's text mininghttps://conductscience.org/library/genes/2244NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39726468

GET https://conductscience.org/api/papers/v1/39726468/references?page=2